STILBCESTROL DIPHOSPHATE (HONVAN) IN THE TREATMENT OF ACUTE URINARY RETENTION DUE TO PROSTATIC CARCINOMA1

Wiley - Tập 37 Số 3 - Trang 314-316 - 1965
Ian Parton1
1Urological Department, Auckland Hospital, New Zealand

Tóm tắt

SUMMARYIn a series of fifty cases (two with extreme difficulty, four with retention and overflow, forty‐four with acute retention) intravenous Honvan was given in daily doses of 500 to 1,000 mg. for five to ten days, the commonest dose being 1,000 mg. daily for five days. In thirty‐three (66 per cent.) cases no surgery was required, the other seventeen (34 per cent.) being treated by transurethral resection. Unless the patient is very old or feeble, prostatic biopsy is essential if any doubt exists about the diagnosis. Once the patient is ambulant and voiding, an oral oestrogen is usually more convenient, as well as being cheaper than an intravenous one. A trial of Honvan is specially recommended for the bad‐risk case of prostatic carcinoma with acute urinary retention.

Từ khóa


Tài liệu tham khảo

10.1111/j.1464-410X.1958.tb03536.x

Fergusson J. D., 1963, Proc. Roy. Soc. Med., 56, 81, 10.1177/003591576305600206

Hansen C. C., 1957, Acta Mr. scand., 114, 398

McKinnon K. J., 1957, Canad. med. Ass. J., 77, 1009

Mullenix R. B., 1951, J. Urol., 65, 608, 10.1016/S0022-5347(17)68528-8

Taylor J. R., 1959, Canad. med. Ass. J., 80, 880

Thông tin
Thông tin xuất bản

Wiley

Tập 37 Số 3

314-316

Thông tin tác giả